Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Manu Morales Sánchez: DOACs in Intermediate Risk Atrial Fibrillation
Sep 29, 2026, 10:28

Manu Morales Sánchez: DOACs in Intermediate Risk Atrial Fibrillation

Manu Morales Sánchez, Doctor of Pharmacy at the University of Salamanca, shared a post on LinkedIn about a recent article by Daehoon Kim et al., published in NEJM, adding:

“Among patients with atrial fibrillation at intermediate risk for stroke, DOAC therapy led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes at 24 months than no anticoagulation. (Funded by the Ministry of Health and Welfare, South Korea, and others; SINGLE-AF ClinicalTrials.gov number, NCT04437654.)”

Title: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk

Authors: Daehoon Kim, Young Soo Lee, Jaemin Shim, Hee Tae Yu, Junbeom Park, Jin-Kyu Park, Il-Young Oh, Ki-Woon Kang, Eue-Keun Choi, Kyoung-Min Park, Hyoung-Seob Park, Dae-Hyeok Kim, Hyung Wook Park, Jun Kim, Jum-Suk Ko, Dongmin Kim, Jong-Youn Kim, Jin-Bae Kim, Jung-Hoon Sung, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Boyoung Joung

Manu Morales Sánchez: DOACs in Intermediate Risk Atrial Fibrillation

Stay updated with Hemostasis Today.